A Phase 3 interventional study of Letrozole and Letrozole in Breast Cancer, sponsored by ETOP IBCSG Partners Foundation. Completed at 164 sites in 20 countries. Open to female participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by ETOP IBCSG Partners Foundation · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 162 studies testing letrozole in Breast Neoplasms — 22 open to participants now, 39 under way, 11 of them phase 3. Letrozole · Breast Neoplasms.
Among the 162 studies testing letrozole in Breast Neoplasms, this one is the 4th largest by enrollment of the 159 interventional ones that give a count, is one of 9 that started in 2007, is one of 41 in phase 3, and was the 53rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →22 of the 162 studies testing letrozole in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Fujian Cancer Hospital · Sites in China
Ages 18+ · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–75 · Women only
Celcuity Inc · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
University of Chicago · Sites in Nigeria
Ages 18+ · Women only
Mridula George, MD · Sites in United States
Ages 60+ · Women only
By country, each count listing its studies:
Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 120 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
162 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 83 · Phase 3 45 · Phase 4 17
First in 1998; this study’s year is marked. 9 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,884 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 95 across the 159 interventional studies. Of the 109 that completed or were terminated, 44 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 162 have an industry lead sponsor. The 10 most frequent:
ETOP IBCSG Partners Foundation is the lead sponsor of 52 studies on the registry; 5 are open to participants now.
29 studies in Breast Neoplasms by ETOP IBCSG Partners Foundation: none open now, 2 under way, 1 of them phase 3. Of 26 finished, 15 (58%) have results posted.
Among the 29 studies in Breast Neoplasms by ETOP IBCSG Partners Foundation, this one is the 2nd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2007, is one of 17 in phase 3, and was the 15th registered.
ETOP IBCSG Partners Foundation’s Breast Neoplasms studies by the year they started, since 1993.
8 of the studies testing letrozole in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04486911Shengjing HospitalPyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | 2026-12-01 |
| NCT05286437National Cancer Centre, SingaporePhase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
| NCT02562118National University Hospital, SingaporeNeoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 162 studies testing letrozole in Breast Neoplasms, from their registry updates:
Among ETOP IBCSG Partners Foundation’s 29 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known which regimen of letrozole is more effective in postmenopausal women who have received hormone therapy for early-stage breast cancer.
PURPOSE: This randomized phase III trial is comparing two different regimens of letrozole in preventing cancer in postmenopausal women who have received 4-6 years of hormone therapy for hormone receptor-positive, lymph node-positive, early-stage breast cancer.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study. Patients are stratified according to treatment center and type of prior endocrine therapy (selective estrogen receptor modulators [SERMs] alone vs aromatase inhibitors [AIs] alone vs both SERMs and AIs each for at least 1 month). Patients are randomized to 1 of 2 treatment arms.
After completion of study therapy, patients are followed annually.
DISEASE CHARACTERISTICS:
Confirmed diagnosis of prior operable, noninflammatory breast cancer meeting the following criteria:
Must have completed 4-6 years of prior adjuvant selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), or a sequential combination of both
PATIENT CHARACTERISTICS:
Must be by any of the following criteria:
Patients 55 years old or younger must have biochemical evidence of definite postmenopausal status (defined as estradiol, LH, and FSH in the postmenopausal range)
PRIOR CONCURRENT THERAPY:
Any type of prior adjuvant therapy allowed including, but not limited to, any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Continuous letrozole: 5 years continuously (2.5 mg Letrozole daily)
Drug: Letrozole
Intermittent letrozole: 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
Drug: Letrozole
Disease-free Survival (DFS)
Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.
Time frame: 5-year estimates, reported at a median follow-up of 60 months
Overall Survival
Duration of time from randomization to death from any cause, or was censored at the date last known alive. (Note, for patients who withdrew consent or were lost to follow-up but follow-up for survival was possible through hospital or registry records, OS was censored at the date last known alive rather than date of last follow-up/withdrawn consent).
Time frame: 5-year estimates, reported at a median follow-up of 60 months
Distant Recurrence-free Interval (DRFI)
Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.\* \*This endpoint replaced DDFS, which was specified in the protocol
Time frame: 5-year estimates, reported at a median follow-up of 60 months
Breast Cancer-free Interval
Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event.
Time frame: 5-year estimates, reported at a median follow-up of 60 months
| Milestone | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| Started | 2441 | 2443 |
| Completed | 2426 | 2425 |
| Not completed | 15 | 18 |
Duration of time from randomization to the first indication of the following events: invasive recurrence at local (including recurrence restricted to the breast after breast conserving treatment), regional or distant sites; a new invasive cancer in the contralateral breast; any second (non-breast) invasive malignancy; or a death without prior cancer event. Appearance of DCIS or LCIS either in the ipsilateral or in the contralateral breast was not be considered as an event for DFS. In the absence of an event, DFS was censored at the date of last follow-up visit.
| percentage of patients | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| Disease-free Survival (DFS) | 87.5 (86 to 88.8) | 85.8 (84.2 to 87.2) |
Duration of time from randomization to death from any cause, or was censored at the date last known alive. (Note, for patients who withdrew consent or were lost to follow-up but follow-up for survival was possible through hospital or registry records, OS was censored at the date last known alive rather than date of last follow-up/withdrawn consent).
| percentage of patients | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| Overall Survival | 93.7 (92.6 to 94.7) | 94.3 (93.2 to 95.2) |
Duration of time from randomization to the first indication of invasive breast recurrence at a distant site. In the absence of an event, DRFI was censored at the date of last follow-up visit or date or death without distant recurrence.\* \*This endpoint replaced DDFS, which was specified in the protocol
| percentage of patients | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| Distant Recurrence-free Interval (DRFI) | 92.5 (91.3 to 93.5) | 93.2 (92 to 94.2) |
Duration of time from randomization to the first indication of the following events: invasive breast recurrence at local, regional or distant sites; a new invasive cancer in the contralateral breast (second non-breast malignancies are ignored). In the absence of an event, BCFI was censored at the date of last follow-up visit or date of death without prior breast cancer event.
| percentage of patients | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| Breast Cancer-free Interval | 91.2 (89.9 to 92.3) | 90.9 (89.6 to 92.1) |
Collected over during or within 30 days after stopping study treatment. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Continuous Letrozole | 170/2,426 (7%) | 1,004/2,411 (41.6%) | 2,257/2,411 (93.6%) |
| Arm B: Intermittent Letrozole | 146/2,425 (6%) | 1,052/2,417 (43.5%) | 2,261/2,417 (93.5%) |
| Event | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| HypertensionVascular disorders | 517/2411 | 584/2417 |
| Pain - JointMusculoskeletal and connective tissue disorders | 151/2411 | 139/2417 |
| Hot flashes/flushesVascular disorders | 70/2411 | 59/2417 |
| FractureInjury, poisoning and procedural complications | 66/2411 | 62/2417 |
| Mood alteration - depressionPsychiatric disorders | 54/2411 | 61/2417 |
| InsomniaPsychiatric disorders | 59/2411 | 52/2417 |
| Fatigue (asthenia, lethargy, malaise)General disorders | 58/2411 | 48/2417 |
| Pain - BoneMusculoskeletal and connective tissue disorders | 58/2411 | 46/2417 |
| Pain - MuscleMusculoskeletal and connective tissue disorders | 54/2411 | 53/2417 |
| ObesityMetabolism and nutrition disorders | 37/2411 | 42/2417 |
| Event | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole |
|---|---|---|
| Pain - JointMusculoskeletal and connective tissue disorders | 1506/2411 | 1453/2417 |
| Hot flashes/flushesVascular disorders | 1240/2411 | 1217/2417 |
| OsteoporosisMusculoskeletal and connective tissue disorders | 1113/2411 | 1119/2417 |
| Fatigue (asthenia, lethargy, malaise)General disorders | 1025/2411 | 954/2417 |
| InsomniaPsychiatric disorders | 983/2411 | 961/2417 |
| Pain - MuscleMusculoskeletal and connective tissue disorders | 841/2411 | 818/2417 |
| Mood alteration - depressionPsychiatric disorders | 767/2411 | 762/2417 |
| Pain - BoneMusculoskeletal and connective tissue disorders | 634/2411 | 613/2417 |
| HypertensionVascular disorders | 539/2411 | 493/2417 |
| FractureInjury, poisoning and procedural complications | 148/2411 | 136/2417 |
Randomized patients, regardless of eligibility status; exceptions were patients who immediately withdrew consent prior to treatment initiation and declined all participation, patients determined to be without adequate documentation of informed consent, and/or patients at a participating center determined not to be compliant with protocol procedures
| Age, Customized(Participants) | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole | Total |
|---|---|---|---|
| <55 | 668 | 671 | 1339 |
| 55-59 | 504 | 496 | 1000 |
| 60-64 | 451 | 471 | 922 |
| 65-69 | 400 | 375 | 775 |
| 70+ | 383 | 412 | 795 |
| Sex: Female, Male(Participants) | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole | Total |
|---|---|---|---|
| Female | 2426 | 2425 | 4851 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole | Total |
|---|---|---|---|
| White/Caucasian | 2199 | 2211 | 4410 |
| Black | 10 | 9 | 19 |
| Asian | 119 | 121 | 240 |
| Other | 97 | 83 | 180 |
| Unknown | 1 | 1 | 2 |
| Region of Enrollment(participants) | Arm A: Continuous Letrozole | Arm B: Intermittent Letrozole | Total |
|---|---|---|---|
| Hungary | 78 | 77 | 155 |
| United States | 21 | 19 | 40 |
| Japan | 93 | 99 | 192 |
| United Kingdom | 217 | 216 | 433 |
| Switzerland | 159 | 159 | 318 |
| India | 8 | 8 | 16 |
| Russia | 22 | 21 | 43 |
| Spain | 137 | 134 | 271 |
| New Zealand | 10 | 9 | 19 |
| Austria | 88 | 92 | 180 |
| Sweden | 104 | 105 | 209 |
| Belgium | 509 | 520 | 1029 |
| Denmark | 223 | 218 | 441 |
| Italy | 287 | 291 | 578 |
| South Africa | 28 | 28 | 56 |
| Australia | 182 | 171 | 353 |
| Chile | 70 | 70 | 140 |
| France | 14 | 16 | 30 |
| Peru | 33 | 33 | 66 |
| Germany | 146 | 145 | 291 |
Showing the first 100 of 164 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Aug 2007, a primary completion of Apr 2018 and a completion of May 2019. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letrozole
ETOP IBCSG Partners Foundation